about
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.High natural killer cell number might identify stroke patients at risk of developing infections.Reliability of measuring regional callosal atrophy in neurodegenerative diseases.Population Pharmacokinetic Approach Applied to Positron Emission Tomography: Computed Tomography for Tumor Tissue Identification in Patients with Glioma.Reliable measurements of brain atrophy in individual patients with multiple sclerosis.Comparison of Several White Matter Tracts in Feline and Canine Brain by Using Magnetic Resonance Diffusion Tensor Imaging.Central nervous system gadolinium accumulation in patients undergoing periodical contrast MRI screening for hereditary tumor syndromes.Diffusion tensor imaging of white matter tracts in the dog brain.Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.Plasma citrulline levels are increased in patients with multiple sclerosis.A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER).Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumabRole of cerebral hypoperfusion in multiple sclerosis (ROCHIMS): study protocol for a proof-of-concept randomized controlled trial with bosentanMigrainous Headache Accompanied by Hemi-Atrophy of the Tongue in Carotid Artery DissectionA focused 35-minute whole body MRI screening protocol for patients with von Hippel-Lindau diseasePost-stroke infections associated with spleen volume reduction: A pilot study
P50
Q33426222-4004FF9E-FEDA-4851-A8A9-A7B23F0E0ADDQ35105751-E1533A53-A868-41C5-BB83-DEFFC540ED28Q37391221-10F8CC32-9199-4D48-9A33-15D8772DA330Q39084819-B9566984-5848-4094-94F5-1F2CFD96B42AQ39335452-5C71F3F7-1067-4E9D-AA15-9C43DE7C3B89Q46415865-25917651-9C0F-4703-A896-36BF7DF672CEQ47875932-74D99F99-67DD-4660-8237-558B179C7004Q48191534-813A429E-4453-4335-B396-130E05F3AF29Q48865058-0D176BC3-6E64-46C4-ADB1-E711F7FF6D61Q52639770-57C741E2-5560-4BE7-96AB-ACF11C7CC808Q55333193-8E9EC5DA-67A1-4173-9D57-C0D04833F477Q56889910-C63829D2-FAE0-4D45-B33F-2A128772AF66Q64096347-53B3E22B-2331-4FB1-85C9-F997A4E64B9CQ91477767-94B1031D-38D0-4FC7-80EB-BA8F1F733AADQ92434641-E1261238-3EB0-411D-9A9D-92161E88E1C1Q94553123-25FF08C2-0C1D-43EE-8FB2-9C308EFA0FD5
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Anne Vanbinst
@en
Anne Vanbinst
@nl
type
label
Anne Vanbinst
@en
Anne Vanbinst
@nl
prefLabel
Anne Vanbinst
@en
Anne Vanbinst
@nl
P31
P496
0000-0003-4867-6133